Catalog No.S1636 Synonyms: NSC 527017
Molecular Weight(MW): 924.08
Amphotericin B (AmB) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes.
Purity & Quality Control
Choose Selective Anti-infection Inhibitors
|Description||Amphotericin B (AmB) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes.|
Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. Amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14.  Amphotericin B interacts with cholesterol, the major sterol of mammal membranes, thus limiting the usefulness of Amphotericin B due to its relatively high toxicity. Amphotericin B is dispersed as a pre-micellar or as a highly aggregated state in the subphase.  Amphotericin B only kills unicellular Leishmania promastigotes (LPs) when aqueous pores permeable to small cations and anions are formed. Amphotericin B (0.1 mM) induces a polarization potential, indicating K+ leakage in KCl-loaded liposomes suspended in an iso-osmotic sucrose solution. Amphotericin B (0.05 mM) exhibits a nearly total collapse of the negative membrane potential, indicating Na+ entry into the cells. 
|In vivo||Amphotericin B results in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. Amphotericin B markedly reduces PrPSc levels in mice with transmissible subacute spongiform encephalopathies (TSSE).  Amphotericin B exerts a direct effect on Plasmodium falciparum and influences eryptosis of infected erythrocytes, parasitemia and hostsurvival in murine malaria. Amphotericin B tends to delay the increase of parasitemia and significantly delays host death plasmodium berghei-infected mice. |
-  Sau K, et al. J Biol Chem, 2003, 278(39), 37561-37568.
-  Barwicz J, et al. Chem Phys Lipids, 1997, 85(2), 145-155.
-  Ramos H, et al. J Membr Biol, 1996, 152(1), 65-75.
|In vitro||DMSO||22 mg/mL (23.8 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03905447||Recruiting||Drug: PC945|Drug: Standard of Care||Aspergillosis|Lung Transplant Infection||Pulmocide Ltd||September 17 2019||Phase 2|
|NCT03828773||Recruiting||Drug: Posaconazole|Drug: Fluconazole||Candidiasis|Fungal Infection|Acute Myeloid Leukemia|Genetic Predisposition|Aspergillosis||Bochud Pierre-Yves|Swiss National Science Foundation|Centre Hospitalier Universitaire Vaudois||February 11 2019||Not Applicable|
|NCT03814343||Recruiting||Drug: amphotericin B in 30% DMSO|Drug: 30% DMSO||Fungal Infection|Onychomycosis|Fungus Nail||Mahidol University||January 15 2019||Phase 4|
|NCT03399955||Recruiting||Drug: Paromomycin|Drug: Ambisome|Drug: Miltefosine||PKDL - Post-Kala-Azar Dermal Leishmanioid||Drugs for Neglected Diseases||May 9 2018||Phase 2|
|NCT02226705||Unknown status||Procedure: Multiple transnasal endoscopic surgeries||Rhinocerebral Mucormycosis||Assistance Publique - Hôpitaux de Paris||January 2015||Phase 2|
|NCT01845727||Completed||Drug: Topical Amphotericin B at 3%||Cutaneous Leishmaniasis||Drugs for Neglected Diseases||February 2014||Phase 1|Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.